Thymosin Alpha-1
Tα1, N-Acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn
Thymosin Alpha-1 is a potent immunomodulatory peptide that enhances T-lymphocyte function, activates natural killer cells, and strengthens both innate and adaptive immune responses. Originally derived from the thymus gland, it plays a crucial role in immune system maturation and has been extensively studied for treating viral infections, cancer, and immunodeficiency disorders.
Complete Research Database
Adverse Event Frequencies (Clinical Trials)
Clinical Safety Notes
- •GI side effects typically occur during dose escalation
- •Most adverse events are mild to moderate in severity
- •Discontinuation rate due to side effects: ~5.3%
- •No increased risk of pancreatitis in clinical trials
- •Regular monitoring recommended for thyroid function
Medical Disclaimer
Thymosin Alpha-1 is an investigational peptide not approved by the FDA for medical treatment in the United States. This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers before use, especially for immune-related conditions or during medical treatments.